TO UPDATE THE PERFORMANCE WORK STATEMENT FOR RADX TECH PROJECT NO. 2643 - PATHOGENDX, INC. - PATHOGENDX COVID-19 MICROARRAY CLADE VARIANT DETECTION TE

与PathgenDx的解决方案(DetectX-RV)，在接下来的四个月里，我们将在不增加实验室占地面积的情况下，为全国提供25倍的测试能力，不会增加无穷无尽的测试系统线，即时贬值，维持所需的准确测试水平，以及一个解决方案，可以灵活的˜™到市场的需求与不同尺寸的SBS板。我们建议的是在相同的实际测试基板上将测试能力翻两番~在不到4个月的时间内将相同的SBS板从12个井阵列幻灯片优化到96个井，最终达到384个井格式。实施这一战略将每月提供415万次测试，并导致每次测试节省55%和70%的成本。相比之下，使用qRT-PCR技术部署相同的容量，RaDx的资本支出是RaDx的五倍，每次测试成本是RaDx的三倍。

With PathogenDx's solution (DetectX-Rv), over the next four months, we will deliver a 25 fold increase in test capacity for the nation without increasing  lab-real-estate footprint, without adding endless lines of testing systems that depreciate instantly, upholding the level of accurate testing needed, and a solution that can ‘flex’ to the demands of the market with the different sized SBS plates.  What we propose is quadrupling test capacity twice on the same actual test substrate ~ optimizing the same SBS plate from 12 well array slides to 96 wells ultimately to a 384 well format in less than 4 months.   Exercising this strategy will deliver 4.15M tests per month, and result in cost savings of 55% and 70% per test. As a comparison, to deploy the same capacity using qRT-PCR technology, it will cost RaDx five times as much in CapEx and three times more per test cost.